**NEPHROLOGY**

**PAPER – III**

| Time : 3 hours | Max. Marks : 100 |

**Important instructions:**
- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

**Write short notes on:**

<table>
<thead>
<tr>
<th>1.</th>
<th>Acquired renal cystic disease under the following heads:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a) Diagnosis</td>
</tr>
<tr>
<td></td>
<td>b) Prevalence</td>
</tr>
<tr>
<td></td>
<td>c) Complications</td>
</tr>
<tr>
<td></td>
<td>d) Management</td>
</tr>
</tbody>
</table>

| 2. | Registries (National and International) as research tool. |

| 3. | a) Steroid avoidance in renal transplant - pros and cons. |
|    | b) Clinical usage of mTOR inhibitors in renal transplant patients. |

| 4. | Hemodialfiltration in maintenance dialysis patients under the following headings: |
|    | a) Technical requirements. |
|    | b) Global usage pattern. |
|    | c) Clinical outcomes. |

| 5. | ABO incompatible renal transplants under the following headings: |
|    | a) Historical perspective. |
|    | b) Current clinical protocols. |
|    | c) Outcomes as compared to compatible renal transplantation. |

| 6. | Vaccinations under the following headings: |
|    | a) Chronic kidney disease – predialysis and dialysis patients. |
|    | b) Vaccinations to be avoided in post renal transplant patients. |

| 7. | a) Revised Chapel-Hill classification of vasculitis. |
|    | b) Mention the important differences from the previous classification. |

| 8. | a) Enumerate the markers of iron status in CKD with their normal values. |
|    | b) Diagnosis and treatment of iron overload. |
|    | c) Newer erythropoiesis stimulating agents. |

|      | (2+2) |

| P.T.O. |
   b) Diagnosis and treatment of myeloma kidney.  

10. The Transplantation of Human Organs and Tissues Act, 2011  
    under the following heads:  
    a) Important differences from THOA, 1994  
    b) Salient requirements of a centre to be recognized for  
        transplantation.